Tesla Semi Rollout Begins at Nevada Factory 
OpenAI AI Agents Bypassed UN Website Controls in Data Scraping 
Airbus Finds A321neo Fuselage Quality Issue 
Select Water Solutions Shares Surge on $700 Million Pilot Water Deal 
US Appeals Court Upholds Anthropic AI Supply Chain Ban 
Akamai Shares Surge on $11.6B Anthropic AI Cloud Deal 
Dubai’s connectivity remains strong in an uncertain world 
SMBC Eyes 20% VPBank Stake in Vietnam Expansion 
SoftBank Shares Fall as Oracle Flags Stargate Data Center Delay Risk 
Solidigm Eyes $150 Billion IPO as SK Hynix Expands AI Storage Push 
Former OpenAI Data Center Chief Chris Malone Joins Nvidia 
Oura IPO Draws Strong Demand Ahead of $2.2 Billion Offering 
Meta Found Liable in New Mexico Facebook Data Privacy Case 
OpenAI Agents Access U.S. Government Websites During Testing 
OpenAI to Preview GPT-6 Cyber AI Model for Cybersecurity 
EQT Plans €1.7 Billion Sale of Parques Reunidos Stake 
Add as a preferred source on Google
SAN ANTONIO, Texas, May 03, 2017 -- bioAffinity Technologies announced that the European Patent Office (EPO) has issued a patent that protects the Company’s proprietary CyPath® technology for the early detection of lung cancer through 2030.
Titled “System and Method for Analyzing Samples Labeled with 5, 10, 15, 20 Tetrakis (4-Carboxyphenyl) Porphine (TCPP),” the EPO patent for bioAffinity’s platform test for early cancer detection will significantly increase bioAffinity’s intellectual property (IP) portfolio that currently consists of 43 awarded patents in 22 countries.
bioAffinity’s porphyrin-based CyPath® bio-label preferentially binds to cancer cells, giving them a distinctive fluorescence that is detectable and measurable by flow cytometry. CyPath® Lung, bioAffinity’s initial product, is designed to be a highly accurate, non-invasive, early-stage lung cancer diagnostic for use by patients at risk for lung cancer.
“According to the World Health Organization, nearly 30 percent of European adults are smokers, and smoking among adolescents is on the rise,” bioAffinity President and CEO Maria Zannes said. “Tobacco use causes 16 percent of all deaths in the adult population over 30 years of age. We expect our CyPath® product to have a significant positive impact on early detection of lung cancer in the European Union.”
bioAffinity is focused on the commercialization of accurate, non-invasive diagnostics and life-saving targeted therapeutics for multiple cancers. CyPath® Lung is a simple and cost-effective diagnostic, which will make it particularly valuable in countries with large populations and broad economic and social demographics.
About bioAffinity Technologies, Inc.
bioAffinity Technologies, Inc. (www.bioaffinitytech.com) is a privately held development-stage company addressing the significant unmet need for non-invasive, early-stage cancer diagnosis and treatment. The Company develops proprietary in-vitro diagnostic tests and targeted cancer therapeutics using breakthrough technology that preferentially targets cancer cells. Research and optimization of its platform technology is conducted in bioAffinity Technologies’ laboratories and at the University of Texas Health Science Center at San Antonio through a collaborative research agreement. The Company’s platform technology will be developed to diagnose, monitor and treat many cancers.
Contact: Maria Zannes, 505.400.9747
